[FINANCIAL] Specialty Pharma · PE
Continuation Vehicle · Secondaries —
Closed February 13, 2026 — Announced March 18, 2026
QHP Capital Closes $1.1B Continuation
Vehicle for Azurity Pharmaceuticals, Anchored by HarbourVest
A sophisticated PE liquidity solution: QHP Capital retains
control of its flagship specialty pharma portfolio company through a
single-asset continuation vehicle — providing exit liquidity to existing LPs
while bringing in HarbourVest, Pantheon, and Audax as new long-term investors
to fund Azurity's next acquisition-led growth phase.
DEAL SNAPSHOT
|
CV SIZE $1.1 Billion |
ANNOUNCED March 18, 2026 |
|
TRANSACTION TYPE Single-Asset
Continuation Vehicle (GP-Led Secondary) |
LEAD NEW INVESTOR HarbourVest Partners LLC |
|
CLOSED February 13, 2026 |
CO-INVESTORS Pantheon Ventures +
Audax Strategic Capital |
THE PARTIES
|
ACQUIRER / LEAD INVESTOR QHP Capital, L.P. (GP) +
HarbourVest Partners (lead LP) QHP Capital is
a Research Triangle Park, NC-based PE firm investing in life sciences and
pharma services companies, rooted in the legacy of Quintiles (now IQVIA) and
NovaQuest Capital Management. Jeff Edwards (Partner) led the transaction.
HarbourVest Partners (Boston) is one of the world's largest fund-of-funds and
secondary investors, with $100B+ in AUM — acting as lead investor and primary
new LP in the continuation vehicle. |
PORTFOLIO COMPANY Azurity Pharmaceuticals,
Inc. Woburn,
MA-based specialty pharmaceutical company focused on delivering medicines to
overlooked and underserved patients. CEO Ronald Scarboro. 50+ medicines
across 10 dosage forms and 10 therapeutic areas. Global footprint in 50+
countries. QHP has owned Azurity for 6+ years, during which the company has
grown substantially through organic growth and acquisitions including Covis
Pharma (acquired March 2025). The CV provides acquisition capital for
Azurity's next M&A phase. |
WHAT IS A CONTINUATION VEHICLE?
A GP-led
continuation vehicle (CV) — also called a GP-led secondary — is a mechanism
that allows a private equity firm to hold a portfolio company beyond the
typical fund lifecycle, providing existing LPs with a choice: (1) sell their
stakes at the CV's implied valuation and realize returns now, or (2) roll into
the new vehicle and maintain exposure to the company's future growth. New
investors (HarbourVest, Pantheon, Audax) provide the capital to buy out the
exiting LPs while QHP remains in control.
QHP's Azurity CV
is structured as a single-asset vehicle — meaning the $1.1B is entirely
committed to Azurity rather than a diversified portfolio. HarbourVest led the
transaction; Pantheon participated as a significant LP; Audax Strategic Capital
contributed both as a CV syndicate investor and through a separate structured
growth investment that provides additional acquisition capital. The transaction
was disclosed on March 18, 2026, although it closed on February 13.
"This CV reflects our strong conviction in Azurity's strategy and
leadership. The capital supports Azurity's continued organic growth, business
development, and potential strategic M&A."
— Jeff Edwards,
Partner, QHP Capital
STRATEGIC CONTEXT
GP-led
continuation vehicles have become one of the most active segments of the
private equity secondaries market in 2024-2026, as GPs seek to hold quality
assets through their full value creation arc rather than selling prematurely to
hit fund return timelines. For Azurity specifically, the CV structure provides
acquisition firepower for continued consolidation in the specialty pharma
market — where Azurity has identified additional bolt-on targets in its
therapeutic areas of focus.
Audax Strategic
Capital's separate structured growth investment alongside the CV is notable: it
represents an additional capital layer specifically earmarked for M&A, not
just liquidity, giving Azurity a well-capitalized war chest as it enters what QHP
describes as "the next phase of growth."
ADVISORS
GP
Financial Advisor (QHP): Goldman
Sachs & Co. LLC
GP
Placement Agent (QHP): Eaton Partners
(a division of Stifel Nichols)
GP Legal
Advisor (QHP): Ropes & Gray LLP
Lead LP
Legal Advisor (HarbourVest): Kirkland
& Ellis LLP